Impact of laser trabeculoplasty on Trabectome® outcomes.
OBJECTIVE
To report the impact of prior laser trabeculoplasty on clinical outcomes of Trabectome (NeoMedix Corporation, Tustin, CA) surgery.


METHODS
This is a retrospective, non-comparative study of consecutive cases of Trabectome surgery with 36 months of follow-up. Main outcome measures were intraocular pressure (IOP), number of glaucoma medications, and the occurrence of secondary procedures.


RESULTS
In the trabeculoplasty group, mean IOP measured 16.5 +/- 4.0 mm Hg with an average decrease of 24% from preoperative IOP at 12 months. In eyes without previous trabeculoplasty, IOP measured 15.7 +/- 3.0 mm Hg with an average decrease of 30% at 12 months. Adjunctive medications decreased to 2.1 and 1.5 glaucoma medications, respectively. Secondary procedures were performed in 12% and 10% of eyes in each group.


CONCLUSIONS
Previous laser trabeculoplasty does not appear to significantly impact IOP, but may increase the need for glaucoma medication in patients undergoing Trabectome surgery.
Vold
Steven D
SD
Boozman-Hof Regional Eye Clinic, PA, 3737 West Walnut, Rogers, AR 72756, USA.
Dustin
Laurie
L
D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D053685:Laser Therapy; D008297:Male; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014129:Trabecular Meshwork / Q000601:surgery*; D014130:Trabeculectomy / Q000295:instrumentation*; D016896:Treatment Outcome
D000959:Antihypertensive Agents